Subjective Experience Following Psilocybin
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Calgary
About this trial
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects of psilocybin.
Eligibility criteria
Qualifiers
Individuals of all sexes, gender identities, and ethnicities
Ages 18 to 65 years of age at the time of screening
Ability to read/write in English
Agree not to consume psychoactive drugs 24 hours before dosing sessions or consume psychedelics during duration of study participation
Disqualifiers
Any notable abnormality on electrocardiogram or routine medical blood or urinalysis laboratory tests
Current psychiatric diagnoses, such as: major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, moderate to severe substance use disorders, eating disorders, personality disorders, post-traumatic stress disorder
Lifetime or current psychiatric diagnoses of: psychosis, schizophrenia, bipolar disorder
Family history: a first- or second degree relative with a history of schizophrenia or other psychotic disorders, bipolar I or II
Trial design
Treatments tested in this trial
- Psilocybin high-dose
- Psilocybin low-dose
- Risperidone 1 MG
- Placebo
Treatment groups
128 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov